{"id":"https://openalex.org/W3084742701","doi":null,"title":"Abstract 13655: Healthcare Resource Utilization Among Empagliflozin Initiators With and Without Cardiovascular Disease versus DPP4i in a Commercially-Insured Routine Care Population: An Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","display_name":"Abstract 13655: Healthcare Resource Utilization Among Empagliflozin Initiators With and Without Cardiovascular Disease versus DPP4i in a Commercially-Insured Routine Care Population: An Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","publication_year":2019,"publication_date":"2019-11-19","ids":{"openalex":"https://openalex.org/W3084742701","mag":"3084742701"},"language":"en","primary_location":{"id":"mag:3084742701","doi":null,"is_oa":false,"landing_page_url":"https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.13655","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Circulation","raw_type":null},"volume":null,"type":"conference-abstract","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044094148","display_name":"Mehdi Najafzadeh","orcid":"https://orcid.org/0000-0003-4503-1057","observed_orcids":["https://orcid.org/0000-0003-4503-1057"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mehdi Najafzadeh","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4503-1057","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102890723","display_name":"Ajinkya M Pawar","orcid":"https://orcid.org/0000-0002-8585-9505","observed_orcids":["https://orcid.org/0000-0002-8585-9505"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ajinkya Pawar","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8585-9505","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004416630","display_name":"Sebastian Schneewei\u00df","orcid":"https://orcid.org/0000-0003-2575-467X","observed_orcids":["https://orcid.org/0000-0003-2575-467X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sebastian Schneewei\u00df","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037108542","display_name":"Anouk D\u00e9ruaz\u2010Luyet","orcid":"https://orcid.org/0000-0001-7396-7392","observed_orcids":["https://orcid.org/0000-0001-7396-7392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anouk D\u00e9ruaz\u2010Luyet","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7396-7392","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036238582","display_name":"Kimberly Goodnow Brodovicz","orcid":"https://orcid.org/0000-0001-8275-1649","observed_orcids":["https://orcid.org/0000-0001-8275-1649"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kimberly G. Brodovicz","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8275-1649","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107892362","display_name":"Anastasia Ustyugova","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anastasia Ustyugova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110661941","display_name":"Nileesa Gautam","orcid":"https://orcid.org/0009-0002-3643-433X","observed_orcids":["https://orcid.org/0009-0002-3643-433X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nileesa Gautam","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5044474781","display_name":"Elisabetta Patorno","orcid":"https://orcid.org/0000-0002-8809-9898","observed_orcids":["https://orcid.org/0000-0002-8809-9898"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elisabetta Patorno","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8809-9898","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.00279999990016222,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9229999780654907},{"id":"https://openalex.org/keywords/healthcare-resource-utilization","display_name":"healthcare resource utilization","score":0.9330000281333923},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.902999997138977},{"id":"https://openalex.org/keywords/cardiovascular-disease","display_name":"cardiovascular disease","score":0.984000027179718},{"id":"https://openalex.org/keywords/heart-failure-hospitalization","display_name":"heart failure hospitalization","score":0.8759999871253967},{"id":"https://openalex.org/keywords/cardiovascular-mortality","display_name":"cardiovascular mortality","score":0.7319999933242798},{"id":"https://openalex.org/keywords/commercially-insured-patients","display_name":"commercially insured patients","score":0.7039999961853027},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.7369999885559082}],"concepts":[{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.997894287109375},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9584972262382507},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5925526022911072},{"id":"https://openalex.org/C2780652884","wikidata":"https://www.wikidata.org/wiki/Q5323607","display_name":"EMPA","level":3,"score":0.5501329898834229},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.520001232624054},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.5078852772712708},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5042186975479126},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.476126492023468},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4393543004989624},{"id":"https://openalex.org/C3018284874","wikidata":"https://www.wikidata.org/wiki/Q389735","display_name":"Cardiovascular health","level":3,"score":0.4238881468772888},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.3666127920150757},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30823051929473877},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.127770334482193},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.0850365161895752},{"id":"https://openalex.org/C199289684","wikidata":"https://www.wikidata.org/wiki/Q83353","display_name":"Mineralogy","level":1,"score":0.0},{"id":"https://openalex.org/C138411078","wikidata":"https://www.wikidata.org/wiki/Q911272","display_name":"Electron microprobe","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3084742701","doi":null,"is_oa":false,"landing_page_url":"https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.13655","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Circulation","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3175700949","https://openalex.org/W3010207927","https://openalex.org/W4295338603","https://openalex.org/W3137709426","https://openalex.org/W3176942856","https://openalex.org/W3035706815","https://openalex.org/W3176817582","https://openalex.org/W2970334842","https://openalex.org/W2904797991","https://openalex.org/W4403353903"],"abstract_inverted_index":{"Empagliflozin":[0],"(EMPA)":[1],"reduced":[2],"the":[3],"risk":[4],"of":[5],"cardiovascular":[6],"death":[7],"by":[8,12,18],"38%,":[9],"all-cause":[10],"mortality":[11],"32%,":[13],"and":[14,27],"heart":[15],"failure":[16],"hospitalization":[17],"35%":[19],"in":[20],"adults":[21],"with":[22],"type":[23],"2":[24],"diabetes":[25],"(T2D)":[26],"established":[28],"CV":[29],"di...":[30]},"counts_by_year":[{"year":2020,"cited_by_count":2}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2020-09-21T00:00:00"}